This lovely set from @jinx.gels can represent either an opal with its chunky glitter or a tourmaline with its pink color.

Colour and tradition converge in the Haldi and Mehendi wardrobe. This is a day to play, to kick back, to ease into the series ...

Step-out hole RY-25-06 intersected 210 m of hornfels with an average sheeted vein density of 13 per metre, extending the zone of abundant veining along strike and down-dip VANCOUVER, BC / ACCESS Newsw ...

Guava, a beloved tropical fruit, comes in two main types: white and pink. Both are nutritional powerhouses, boosting immunity and aiding digestion. However, they differ in taste, texture, and nutrient ...

This news release contains forward-looking information and statements (collectively, "forward-looking information") within the meaning of applicable securities laws ...

Ready for their Emmy close-up, the latest high-jewelry debuts put an accent on boldly hued gemstones and nature-inspired designs. All prices upon request, of course.

Novartis has agreed to acquire Tourmaline Bio, a clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular ...

Cardiovascular disease can be managed with drugs that take various approaches, but few of them work by reducing inflammation. Novartis is getting an anti-inflammatory drug candidate through its $1.4 ...

BERLIN (Reuters) - Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on ...

Novartis AG agreed to buy Tourmaline Bio Inc. in a deal valued at about $1.4 billion as the Swiss drugmaker continues to pursue bolt-on deals to boost its drug pipeline. The company will pay $48 per ...

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of ...

Novartis to acquire Tourmaline Bio for $1.4 billionBERLIN (Reuters) - Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a ...